Amendment to Employment Agreement

2nd Amendment to Employment Agreement

 

EXHIBIT 10.9A

 

TERCICA MEDICA, INC.

 

KEY EMPLOYEE AGREEMENT

FOR

JOHN A. SCARLETT, M.D.

 

This KEY EMPLOYEE AGREEMENT (“Agreement”), dated as of February 27, 2002 (the “Employment Date”), is entered into by and between JOHN A. SCARLETT, M.D. (“Executive”) and TERCICA MEDICA, INC., a Delaware corporation (the “Company”).

 

WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for his services; and

 

WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:

 

1.    Position, Duties and Responsibilities.

 

(a)    The Company will employ Executive in the position of Chief Executive Officer (“CEO”). As CEO, Executive will report to the Company’s Board of Directors (the “Board”) and will perform the duties customarily associated with this position and such other duties assigned by the Board. Executive will report exclusively to the Board, and all employees other than the Chairman of the Board of Directors will report exclusively to Executive or his designee(s). As of the Employment Date, Ross G. Clark will be the Company’s Chairman of the Board of Directors.

 

(b)    Executive agrees to exercise the highest degree of professionalism, utilize his expertise and creative talents, and devote all of his business time and attention (except for any outside business activities approved by the Board and except for periods of vacation and reasonable periods of illness or other incapacity permitted by the Company’s general employment policies) in performing his duties as CEO. Executive intends to retain a residence in Austin, Texas, but shall work at the Company’s headquarters in the San Francisco Bay Area.

 

(c)    The Company intends that Executive be nominated and elected as a member of the Board, to serve in such position at all times during which Executive is serving as the Company’s CEO, and it will use its best efforts to cause this to occur as soon as possible following commencement of Executive’s employment.


2.    Compensation and Employee Benefits.

 

2.1    Base Salary, Bonuses and Benefits.

 

(a)    Base Salary.    Executive’s initial annual base salary will be two hundred and eighty thousand dollars ($280,000), less standard payroll deductions and withholdings. Until the Financing Event (defined in the Restricted Stock Purchase Agreement, dated the Employment Date, between the parties (the “Restricted Stock Purchase Agreement”)), the Company will pay Executive, on its regular payroll schedule, a portion of his base salary consistent with the amount of salary paid to other executive-level employees of the Company, and payment of the remainder of Executive’s base salary will be deferred. Promptly (and in any event within three business days) after the occurrence of the Financing Event, the Company will provide payment to Executive for the total amount of his deferred base salary. Effective on the Financing Event, the Company will also commence paying Executive at his full base salary rate on its regular payroll schedule. The Board will review Executive’s base salary at least annually, and the Board may increase (but not decrease) Executive’s salary in its discretion; provided, however, that the Company may decrease Executive’s salary as part of a salary reduction generally applicable to the Company’s executive officers.

 

(b)    Bonuses.    During his employment, Executive will be entitled to participate in a Company bonus program, if any, applicable to the Company’s executive-level employees generally that may be established in the future

 

(c)    Employee Benefits.    Executive shall be entitled to all benefits, including health and disability benefits, for which he is or may become eligible under the terms and conditions of the standard Company benefits plans which may be in effect from time to time and provided by the Company to its employees generally.

 

(d)    Vacation Accrual.    Executive will be entitled to vacation at a rate of five (5) weeks per year; provided that vacation accrual shall be limited to four (4) weeks in the aggregate.

 

(e)    Housing Allowance and Reimbursement For Personal Travel.    During Executive’s employment so long as his primary residence is located in Austin, Texas, the Company will provide Executive with reimbursement for out-of-pocket rent of not more than $2,000 per month (the “Housing Allowance”) actually incurred by Executive for his San Francisco Bay Area housing. In addition, during Executive’s employment so long as his primary residence is located in Austin, Texas, the Company will reimburse Executive for the actually incurred, reasonable out-of-pocket costs of his weekly commute between the San Francisco Bay Area and Austin, Texas; provided that in no event shall such amounts provided to Executive pursuant to this sentence exceed in the aggregate $20,000 per year.

 

2


2.2    Stock and Stock Option Awards.

 

(a)    Purchase of Founders’ Stock.    On the Employment Date and pursuant to the Restricted Stock Purchase Agreement, Executive will be permitted to purchase two hundred five thousand one hundred (205,100) shares of Company Common Stock (an amount equal to approximately 18.15% of the Company’s outstanding capitalization as of such date, subsequent to and taking into account the sale of such shares to Executive, and excluding outstanding bridge notes and warrants), at a price of $0.01 per share (the “Founders’ Shares”).

 

(b)    Option Grant.    Within 30 days following the closing of the first Financing Event (defined in the Restricted Stock Purchase Agreement), the Company will grant Executive a stock option (the “Option”) to purchase shares of the Company’s Common Stock representing, when added to the Founders’ Shares referenced above, 8.5% of the Company’s total outstanding equity shares calculated on a fully-diluted basis subsequent to and taking into account the Financing Event. The exercise price per share of the Option will be equal to the fair market value of the Company’s Common Stock on the date of the grant as determined by the Board. The Option will be subject to the following vesting schedule: as long as Executive remains employed by the Company at such times, twenty-five percent (25%) of the Option shares will be vested and immediately exercisable upon the first anniversary of the date of grant, and the remaining Option shares will vest in thirty-six (36) equal monthly installments thereafter, so as to be one hundred percent (100%) vested on the four (4) year anniversary of the date of Option grant.

 

(c)    Definition of Change in Control.    For purposes of this Agreement, the term “Change of Control” means the consummation of any of the following transactions:

 

(1)    the stockholders of the Company approve a business combination (such as a merger or consolidation) of the Company with any other corporation or other type of business entity (such as a limited liability company), other than a business combination which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such controlling surviving entity outstanding immediately after such business combination; provided, however, that a Financing Event shall not constitute a Change of Control; or

 

(2)    the sale, lease, exchange or other transfer or disposition by the Company of all or substantially all of the Company’s assets by value.

 

(d)    Parachute Payments.    If any payment or benefit Executive would receive pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or

 

3


(y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order: reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive’s stock awards unless Executive elects in writing a different order for cancellation.

 

(1)    The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.

 

(2)    The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.

 

3.    Term of Employment; Termination.

 

(a)    Term of Employment.    This Agreement will become effective as of the first date by which both parties have executed it, and will remain in effect unless terminated as specified herein. Executive’s employment will be at-will and, subject to the terms of this Agreement, either Executive or the Company may terminate the employment relationship at any time upon notice to the other, with or without Cause (defined herein), Good Reason (defined herein), or advance notice.

 

4


(b)    Severance Benefits For Termination Without Cause or Resignation for Good Reason.

 

(1)    Termination/Resignation Prior to a Change of Control or on or After Twelve Months Following a Change of Control.    If the Company terminates Executive’s employment without Cause (defined herein) or Executive resigns his employment for Good Reason (defined herein) prior to a Change of Control or on or after twelve (12) months following a Change of Control, Executive shall receive the following severance benefits from the Company (collectively, the “Severance Benefits”): (i) at Executive’s sole election, he will either continue to receive his annual base salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(d)(ii), he will receive payments equal to his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings, on the Company’s standard payroll dates for the period from the termination effective date and continuing for six months (twelve (12) months, in the event at least one (1) year has elapsed from the Employment Date to the termination effective date) thereafter, or, within five (5) business days following the termination effective date, he will receive a lump sum severance payment equal to six (6) months (twelve (12) months, in the event at least one (1) year has elapsed from the Employment Date to the termination effective date) of his base salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(d)(ii), he will receive a severance payment equal to six (6) months (twelve (12) months, in the event at least one (1) year has elapsed from the Employment Date to the termination effective date) of his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings; (ii) the unvested portions of any and all of Executive’s stock option grants or other equity grants will be subject to accelerated vesting such that the number of shares that would have vested if Executive’s employment continued for twelve (12) months following the termination date will immediately vest and become fully exercisable as of the termination effective date; (iii) subject to Section 3(c) of the Restricted Stock Purchase Agreement with respect to the nonoccurrence of the Financing Event, the Company’s right of repurchase shall lapse as to all Founders’ Shares and (iv) if Executive timely elects to continue his Company-provided group health insurance coverage pursuant to federal COBRA law, the Company will reimburse him for the cost of his COBRA premiums to continue his health insurance coverage for him and his dependents (if applicable) for twelve (12) months following the termination effective date.

 

(2)    Within 12 Months Following a Change of Control.    If the Company terminates Executive’s employment without Cause (defined herein) or Executive resigns his employment for Good Reason (defined herein) within twelve (12) months following a Change of Control, Executive shall receive the following severance benefits from the Company (collectively, the “Severance Benefits”): (i) Executive will continue to receive his annual base salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(d)(ii), he will receive payments equal to his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings, on the Company’s standard payroll dates for the period from the termination effective date and continuing for twelve (12) months thereafter, provided that in order to continue receiving such salary Executive shall not compete with, solicit employees of, or otherwise interfere with the employment relationships of the Company; (ii) the unvested portions

 

5


of any and all of Executive’s stock option grants or other equity grants will be subject to accelerated vesting such that the number of shares that would have vested if Executive’s employment continued for twelve (12) months following the termination date will immediately vest and become fully exercisable as of the termination effective date; (iii) subject to Section 3(c) of the Restricted Stock Purchase Agreement with respect to the nonoccurrence of the Financing Event, the Company’s right of repurchase shall lapse as to all Founders’ Shares and (iv) if Executive timely elects to continue his Company-provided group health insurance coverage pursuant to federal COBRA law, the Company will reimburse him for the cost of his COBRA premiums to continue his health insurance coverage for him and his dependents (if applicable) for eighteen (18) months following the termination effective date.

 

(c)    Definition of Cause for Termination.    For purposes of this Agreement, “Cause” for termination means: (i) Executive’s conviction of any felony; (ii) Executive’s participation in any fraud or act of dishonesty against the Company resulting in material damage to the Company; (iii) Executive’s material breach of this Agreement or his Proprietary Information and Inventions Agreement; or (iv) other wrongful conduct by Executive that in the good faith and reasonable determination of the Board demonstrates Executive’s gross unfitness to serve, provided that Executive is given at least thirty (30) days advance written notice of such conduct and a reasonable opportunity to cure.

 

(d)    Definition of Resignation for Good Reason.    For purposes of this Agreement, “Good Reason” for resignation “Good Reason” shall mean, without Executive’s express written consent (i) a significant reduction of Executive’s duties, position or responsibilities relative to Executive’s duties, position or responsibilities in effect immediately prior to such reduction; provided, however, that a reduction in duties, position or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (as, for example, when, following a Change of Control, the Chief Executive Officer of the Company remains the Chief Executive Officer of a division or subsidiary of the acquirer that contains the Company’s business) shall not constitute a “Good Reason;”; (ii) a reduction by the Company of Executive’s base salary as in effect immediately prior to such reduction (except as part of a base salary reduction generally applicable to executives); or (iii) a material reduction by the Company in the kind or level of employee benefits to which Executive is entitled immediately prior to such reduction with the result that Executive’s overall benefits package is significantly reduced (except as part of a reduction generally applicable to executives); provided, however, that the Company shall have a period of thirty (30) days following receipt of written notice from Executive specifying the grounds for a purported voluntary termination for Good Reason to cure any event or failure that would otherwise constitute Good Reason.

 

4.    Other Activities During Employment.

 

(a)    Except as permitted by Section 4(b) below, during Executive’s employment he agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, or its business or prospects, financial or otherwise.

 

6


(b)    During the term of Executive’s employment by the Company except on behalf of the Company, Executive will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever that is a competitor of the Company (a “Competing Business”); provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities of any Competing Business, so long as his direct holdings in any one such corporation do not in the aggregate constitute more than one percent (1%) of the voting stock of such corporation.

 

5.    Former Employment.

 

(a)    Executive represents and warrants that his employment by the Company will not conflict with and will not be constrained by any prior employment or consulting agreement or relationship. Executive represents and warrants that he does not possess confidential information arising out of prior employment which, in his best judgment, would be utilized in connection with his employment by the Company, except in accordance with agreements between Executive’s former employer and the Company.

 

(b)    If, in spite of the second sentence of Section 5(a), Executive should find that confidential information belonging to any former employer might be usable in connection with the Company’s business, he will not disclose to the Company or use on behalf of the Company any confidential information belonging to any of his former employers (except in accordance with agreements between the Company and any such former employer); but during his employment by the Company, Executive will use in the performance of his duties all information which is generally known and used by persons with training and experience comparable to his own and all information which is common knowledge in the industry or otherwise legally in the public domain.

 

6.    Indemnification of Executive.    The Company shall indemnify Executive for his conduct as a member of the Company’s Board of Directors and as the Company’s CEO to the fullest extent allowed by applicable law. Without limiting the foregoing, Executive shall be entitled to the benefit of the indemnification provisions contained on the date hereof in the Bylaws of the Company.

 

7.    No Offsets or Mitigation.    Unless otherwise expressly provided herein, no payment of salary, bonus or Severance Benefits pursuant to this Agreement shall reduce any other payment or benefit to which Executive is otherwise entitled except pursuant to the express terms under which such other payment or benefit is provided, nor shall a payment or benefit provided other than under this Agreement reduce payment of salary, bonus or Severance Benefit under this Agreement except pursuant to the express terms of this Agreement. The Company shall not offset against any payment of salary, bonus or Severance Benefits under this Agreement or against any stock or stock option grants and the securities receivable thereunder the amount of any claims it or any affiliated entity may have against Executive, including, without limitation, any claims under this Agreement. Payment of salary, bonus and Severance Benefits pursuant to this Agreement, and Executive’s exercise of any stock option grants and his receipt of securities

 

7


thereunder shall not require Executive to mitigate the amount of such payment or receipt by seeking other employment or otherwise.

 

8.    Authorization for Agreement; Absence of Conflicts.    The Company hereby represents that the person executing this Agreement has been duly authorized by the Board to execute this Agreement on its behalf and that this Agreement is a valid, binding and enforceable agreement and not in conflict with any other agreement to which the Company is a party. Except as noted herein, all consents and approvals necessary for the Company to enter into this Agreement have been obtained. There are no conflicts between this Agreement and any laws to which the Company is subject or the Company’s Certificate of Incorporation or Bylaws.

 

9.    Waiver.    If either party should waive any breach of any provisions of this Agreement, he or it will not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

10.    Headings.    The headings of the sections hereof are inserted for convenience only and will not be deemed to constitute a part hereof nor to affect the meaning thereof.

 

11.    Amendment.    This Agreement may not be amended or modified except by a written instrument signed by Executive and a duly authorized member of the Board.

 

12.    Severability.    If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement, and the Agreement should be enforced insofar as possible to achieve the intent of the parties.

 

13.    Right to Work.    As required by law, this Agreement is subject to satisfactory proof of Executive’s right to work in the United States.

 

14.    Governing Law.    This Agreement will be construed and interpreted in accordance with the laws of the State of California.

 

15.    Complete Agreement.    This Agreement and the Common Stock Purchase Agreement referenced herein constitute the complete, final and exclusive embodiment of Executive’s employment agreement with the Company. This Agreement and the Common Stock Purchase Agreement are entered into without reliance upon any promise, warranty or representation, written or oral, other than those expressly contained herein or therein, and supersede any other such promises, warranties, representations or agreements, including without limitation the Consulting Agreement between Company and Executive dated February 27, 2001.

 

8


IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year written below.

 

TERCICA MEDICA, INC.

 

 

By:

 

/s/ Ross Clark

 


 

 

 

Name:

 

Ross Clark

 


 

 

 

Title:

 

Chief Executive Officer and President

 


 

 

 

Date:

 

February 27, 2002

 

Accepted and agreed this

27th day of February, 2002.

 

/s/ John A. Scarlett                                

JOHN A. SCARLETT, M.D.

 

 

 

EXHIBIT 10.9B

 

TERCICA MEDICA, INC.

 

AMENDMENT TO

KEY EMPLOYEE AGREEMENT

FOR

JOHN A. SCARLETT, M.D.

 

This Amendment (the “Amendment”) is made as of May 15, 2002, to the Key Employee Agreement (“Agreement”), dated as of February 27, 2002, entered into by and between JOHN A. SCARLETT, M.D. (“Executive”) and TERCICA MEDICA, INC., a Delaware corporation (the “Company”). All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given them in the Agreement.

 

WHEREAS, Dr. Ross G. Clark has requested that the Company grant him an option (the “Clark Option”) to purchase shares of the Company’s common stock in connection with his execution of a Key Employee Agreement of even date herewith; and

 

WHEREAS, the Company and Executive wish to amend Section 2.2(b) of the Agreement to reflect dilutive events and to reduce the number of shares subject to the Option so that the shares so removed from the Option may be granted to Dr. Clark pursuant to the Clark Option; and

 

WHEREAS, the Company and Executive wish to amend the Agreement to add a new Section 16 to impose those restrictions on Executive’s shares of the Company’s stock that are required by the investors in the Financing Event; and

 

WHEREAS, Executive is a stockholder of the Company and, as such, expects to benefit from the employment of Dr. Clark by the Company and from the Financing Event.

 

NOW, THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.    Section 2.2(b) of the Agreement is amended in its entirety to read in full as follows:

 

(b)    Option Grant.    Within 30 days following the closing of the first Financing Event (defined in the Restricted Stock Purchase Agreement), the Company will grant Executive a stock option (the “Option”) to purchase shares of the Company’s Common Stock representing 5.078% of the Company’s total outstanding equity shares calculated on a fully-diluted basis subsequent to and taking into account the Financing Event. The exercise price per share of the Option will be equal to the fair market value of the Company’s Common Stock on the date of the grant as determined by the Board. The


Option will be subject to the following vesting schedule: as long as Executive remains employed by the Company at such times, twenty-five percent (25%) of the Option shares will be vested and immediately exercisable upon the first anniversary of the date of grant, and the remaining Option shares will vest in thirty-six (36) equal monthly installments thereafter, so as to be one hundred percent (100%) vested on the four (4) year anniversary of the date of Option grant.

 

2.    The Agreement is hereby amended to add the following Section 16:

 

16.    Restrictions on Equity Transfers.

 

(a)    Investors’ Rights Agreement.    Executive understands that the Company intends to enter into investor rights agreements or investors’ rights agreement (collectively, “Investors’ Rights Agreements”) with certain of its investors, including Genentech, Inc. (collectively, the “Investors”), pursuant to which the Company will agree to place certain transfer restrictions on Executive’s equity securities in the Company. Accordingly, Executive agrees not to dispose of any shares of the Company’s Common Stock owned by him (unless the Board, including a majority of the Series A Directors (as that term is used in the Investors’ Rights Agreements), consents to the proposed transfer), until the earliest to occur of the following: (i) there remain outstanding less than 10,000,000 shares of the Series A Preferred Stock purchased by the Investors; (ii) the closing of the Company’s first firm commitment underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended; (iii) the closing of any liquidation, dissolution, or winding up of the Company whether voluntary or involuntary including any sale, exchange, conveyance or other disposition of the capital stock of the Company in a transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company is disposed of, or the sale of all or substantially all of the Company’s assets; and (iv) the eighth anniversary of the first closing of sales of the Company’s Series A Preferred Stock to the Investors. If the relevant provisions of the Investors’ Rights Agreements, as executed, differ from the foregoing provisions of this Section 7(a), this Section 7(a) shall be similarly revised.

 

(b)    ROFR and Co-Sale Agreement.    Executive understands that the Company intends to enter into a right of first refusal and co-sale agreement (the “ROFR and Co-Sale Agreement”) with certain of its investors, which agreement may place certain transfer restrictions on Executive’s equity securities in the Company. Such transfer restrictions may include (i) a right of first refusal in favor of the Company and certain of its investors to purchase Executive’s equity securities in the Company before such equity securities may be sold to third parties and (ii) a co-sale right in favor of certain of the Company’s investors to participate in any proposed sales to third parties of Executive’s equity securities in the Company. Executive hereby agrees to be bound by such provisions of the ROFR and Co-Sale Agreement as a “Restricted Party” thereunder.

 

2


IN WITNESS WHEREOF, the parties have executed this Amendment on the day and year fist written above.

 

TERCICA MEDICA, INC.

 

 

By:

 

/s/ John A. Scarlett

 


 

 

Name:

 

John A. Scarlett

 


 

 

Title:

 

President/CEO

 


 

/s/ John A. Scarlett


JOHN A. SCARLETT, M.D.

 

 

 

 

 

 

 

 

 

 

 

AMENDMENT TO KEY EMPLOYMENT AGREEMENT FOR JOHN A SCARLETT

EXHIBIT 10.9N

 

February 22, 2005

 

John A, Scarlett

6801 St. Andrews Way

Austin, TX 78746

 

Re:    Amendment to Key Employee Agreement

 

Dear Chip:

 

By our signatures below, we hereby agree that effective as of February 22, 2005 this Amendment to Key Employee Agreement amends Section 3 (b) (2) of that certain Key Employee Agreement, dated as of June 23, 2004, as follows:

 

“Within 12 Months Following a Change of Control. If the Company terminates Executive’s employment without Cause (defined herein) or Executive resigns his employment for Good Reason (defined herein) within twelve (12) months following a Change of Control, Executive shall receive the following severance benefits from the Company (collectively, the “Severance Benefits”): (i) Executive will continue to receive his annual base salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(d)(ii), he will receive payments equal to his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings, on the Company’s standard payroll dates for the period from the termination effective date and continuing for twelve (12) months thereafter, provided that in order to continue receiving such salary Executive shall not compete with, solicit employees of, or otherwise interfere with the employment relationships of the Company; (ii) the unvested portions of any and all of Executive’s stock option grants or other equity grants will be subject to accelerated vesting such that the number of shares that would have vested if Executive’s employment continued for twelve (12) months following the termination date will immediately vest and become fully exercisable as of the termination effective date; (iii) subject to Section 3(c) of the Restricted Stock Purchase Agreement with respect to the nonoccurrence of the Financing Event, the Company’s right of repurchase shall lapse as to all Founders’ Shares and (iv) if Executive timely elects to continue his Company-provided group health insurance coverage pursuant to federal COBRA law, the Company will reimburse him for the cost of his COBRA premiums to continue his health insurance coverage for him and his dependents (if applicable) for eighteen (18) months following the termination effective date.”

 

1.


Section 3 (b) (2) above shall be terminated and superseded in its entirety by the following paragraphs and their terms:

 

“Within 12 Months Following a Change of Control. If the Company terminates Executive’s employment without Cause (defined herein) or Executive resigns his employment for Good Reason (defined herein) within twelve (12) months following a Change of Control, Executive shall receive the following severance benefits from the Company (collectively, the “Severance Benefits”): (i) Executive will continue to receive his annual base salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(d)(ii), he will receive payments equal to his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings, on the Company’s standard payroll dates for the period from the termination effective date and continuing for twenty-four (24) months thereafter, provided that in order to continue receiving such salary Executive shall not compete with, solicit employees of, or otherwise interfere with the employment relationships of the Company; (ii) the unvested portions of any and all of Executive’s stock option grants or other equity grants will be subject to accelerated vesting such that all of the shares will immediately vest and become fully exercisable as of the termination effective date; and (iii) if Executive timely elects to continue his Company-provided group health insurance coverage pursuant to federal COBRA law, the Company will reimburse him for the cost of his COBRA premiums to continue his health insurance coverage for him and his dependents (if applicable) for eighteen (18) months following the termination effective date.

 

All severance provisions provided in this Agreement are subject to the parties entering into a final separation agreement containing the Company’s standard form of release of claims in favor of the Company (attached to the Amendment to Key Employee Agreement on Exhibit D) and other standard provisions, including without limitation, those relating to non-disparagement and confidentiality.”

 

Sincerely

 

 

 

 

/s/ Stephen Rosenfield


 

John Scarlett


Stephen N. Rosenfield

 

John A. Scarlett

Senior Vice President of Legal Affairs

 

 

 

 


 


Date

 

Date

 

2.


EXHIBIT D

 

STANDARD FORM OF RELEASE PROVISIONS

 

1. Release of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company and its officers, managers, supervisors, agents and employees. Employee, on his/her own behalf, and on behalf of his/her respective heirs, family members, executors, agents, and assigns, hereby fully and forever releases the Company and its officers, directors, employees, agents, investors, shareholders, administrators, affiliates, divisions, subsidiaries, predecessor and successor corporations, and assigns (“the Releasees”), from, and agree not to sue concerning, any claim, duty, obligation or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess arising from any omissions, acts or facts that have occurred up until and including the Effective Date of this Agreement including, without limitation:

 

(a) any and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of that relationship;

 

(b) any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

 

(c) any and all claims under the law of any jurisdiction including, but not limited to, wrongful discharge of employment; constructive discharge from employment; termination in violation of public policy; discrimination; breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion;

 

(d) any and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, The Worker Adjustment and Retraining Notification Act, the Older Workers Benefit Protection Act; the Family and Medical Leave Act; the California Family Rights Act; the California Fair Employment and Housing Act, and the California Labor Code;

 

(e) any and all claims for violation of the federal, or any state, constitution;

 

D-1


(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

 

(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by Employee as a result of this Agreement; and

 

(h) any and all claims for attorneys’ fees and costs.

 

The Company and Employee agree that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not extend to any obligations incurred under this Agreement.

 

2. Acknowledgement of Waiver of Claims Under ADEA. Employee acknowledges that he/she is waiving and releasing any rights he/she may have under the Age Discrimination in Employment Act of 1967 (“ADEA”) and that this waiver and release is knowing and voluntary. Employee and the Company agree that this waiver and release does not apply to any rights or claims that may arise under ADEA after the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release Agreement is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that he/she has been advised by this writing that:

 

(a) He/she should consult with an attorney prior to executing this Agreement;

 

(b) He/she has up to twenty-one (21) days within which to consider this Agreement;

 

(c) He/she has seven (7) days following his/her execution of this Agreement to revoke this Agreement;

 

(d) this Agreement shall not be effective until the revocation period has expired; and

 

(e) nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law.

 

3. Civil Code Section 1542. Employee represents that he/she is not aware of any claim by him/her other than the claims that are released by this Agreement. Employee acknowledges that he/she has had the opportunity to be advised by legal counsel and is familiar with the provisions of California Civil Code Section 1542, which provides as follows:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

 

D-2


Employee, being aware of said code section, agrees to expressly waive any rights he/she may have thereunder, as well as under any other statute or common law principles of similar effect.

 

4. No Pending or Future Lawsuits. Employee represents that he/she has no lawsuits, claims, or actions pending in his/her name, or on behalf of any other person or entity, against the Company or any other person or entity referred to herein. Employee also represents that he/she does not intend to bring any claims on his/her own behalf or on behalf of any other person or entity against the Company or any other person or entity referred to herein.

 

5. Application for Employment. Employee understands and agrees that, as a condition of this Agreement, he/she shall not be entitled to any employment within the Company, its subsidiaries and he/she hereby waives any right, or alleged right, of employment or re-employment with the Company or its subsidiaries.

 

D-3